Celltrion And Pfizer Cement Victory On Infliximab
Janssen's Cell-Culture Media Patent Not Infringed By Inflectra/Remsima
Celltrion and Pfizer are now two for two in their legal battles with Janssen over US patents shielding the originator's Remicade (infliximab), with a US Court of Appeals once again siding with the biosimilars developers.
You may also be interested in...
Pfizer and Johnson & Johnson have settled long-running US antitrust litigation over claims that contracts and deals for the Remicade brand were set up to dampen competition from infliximab biosimilars.
Pfizer’s Hospira and its biosimilar development partner Celltrion have won a summary judgement from a Massachusetts district court affirming that the cell-culture media they use to produce the Inflectra/Remsima (infliximab-dyyb) biosimilar does not infringe Janssen’s US patent 7,598,083 under the doctrine of equivalents.
With Eagle set to launch its long-awaited vasopressin ANDA product on 17 January, the US firm’s management told investors it was unsure what its launch meant for the 505(b)(2) rival product in the hands of American Regent.